Atomic Precision in Personalized Oncology: AI-Designed Nanomedicines Enabling N-of-1 Cancer Therapy

Rapid advances in AI-driven molecular design, intelligent nanomaterial engineering, and clinical AI systems are reshaping personalized cancer therapy by enabling coordinated innovation across biological scales, from genome regulation to functional protein interactions. At the molecular level, generative platforms such as AlphaProteo and RFdiffusion now support the rapid design of de novo protein binders with high predicted structural accuracy and low-nanomolar affinities. Acting upstream, AlphaGenome interprets genome-wide regulatory variation to predict how single-base changes in noncoding DNA alter gene control mechanisms, facilitating the prioritization of patient-specific pathways and therapeutic targets. Together, these capabilities are transforming computational design from a speculative approach to a reliable molecular engineering workflow. In parallel, clinically validated nanomedicine platforms provide modular architectures that enhance pharmacokinetics, improve therapeutic indices, and modulate tumor–immune interactions, addressing persistent barriers in solid tumor treatment. Integration with AI-enabled experimental platforms, patient-derived organoid systems, spatial and single-cell profiling, quantitative systems pharmacology models, and microfluidic GMP-compatible manufacturing suggests a feasible path toward accelerated, patient-matched nanomedicine development. While challenges remain─including immunogenicity and manufacturing constraints─the convergence of computation, materials engineering, and regulatory science supports a realistic roadmap toward N-of-1 oncology.